Early Statin Use After Type 2 Diabetes Diagnosis Linked to Lower Dementia Risk
A large Danish study found that people who started statins within a year of a type 2 diabetes diagnosis had a 15 percent lower relative risk of dementia over the next decade than those who never started treatment.
People newly diagnosed with type 2 diabetes who started cholesterol-lowering statins within a year of diagnosis had a lower rate of dementia over the following decade than those who never started the drugs, according to a large Danish study presented at the European Society of Cardiology Congress in Munich and published in The Lancet Regional Health - Europe.
The findings matter because type 2 diabetes already raises dementia risk substantially on its own. People with the condition have roughly 1.5 to 2 times the risk of developing dementia compared with the general population, and their cognitive decline tends to progress about twice as fast. A treatment that might chip away at that added risk, using a drug already prescribed to millions of people, would be a meaningful, low-cost intervention if the association holds up.
What the researchers did
Dr. Tummas Ternhamar of Copenhagen University Hospital and colleagues used Danish national health registers to track 132,585 people who had never taken statins before being diagnosed with type 2 diabetes between 2006 and 2019, following them through 2021. They compared three groups: people who never started a statin within five years of diagnosis, those who started within the first year, and those who started between one and five years later.
To reduce the kind of bias that often distorts observational health data, the team used a technique called a clone-censor-weight design, a statistical approach built to mimic the conditions of a randomized trial more closely than a standard observational comparison would. Over a median follow-up of 7.1 years, 2.7 percent of participants developed dementia.
What they found
People who started statins within a year of their diabetes diagnosis had a 15 percent lower relative risk of dementia over 10 years compared with those who never started treatment. Starting later, between one and five years after diagnosis, was associated with a 10 percent lower relative risk, smaller but still meaningfully positive. The pattern held for both men and women.
Put simply, earlier appeared to be better, and any statin use looked better than none, at least in this dataset.
An important caveat
This is registry data, not a randomized controlled trial, and the study's own commentator was direct about what that means. "This was an observational study, so it cannot prove that statins prevent dementia," said Professor Isabel Goncalves of the ESC Communication Committee, who called for further research to confirm the relationship. People who start statins earlier may differ from those who don't in ways researchers can't fully account for, even with a statistical design built to narrow that gap: they may see doctors more regularly, manage their diabetes more closely overall, or share other health behaviors that also lower dementia risk.
That distinction, association rather than proven prevention, is the difference between a promising lead and a settled answer.
Fitting into a bigger picture
The timing lines up with a broader shift in how researchers think about dementia risk. A 2024 Lancet Commission report identified high LDL cholesterol as one of two newly recognized modifiable risk factors for dementia, alongside vision loss, adding to a list of 14 factors the commission estimated could collectively prevent or delay nearly half of dementia cases worldwide if addressed. Statins are already the standard first-line treatment for lowering LDL cholesterol, which is what makes this particular association worth taking seriously rather than dismissing as a statistical coincidence.
What comes next
Confirming a causal effect would likely require a randomized trial specifically designed to test whether early statin use reduces dementia risk in people with type 2 diabetes, something that has not yet been done at this scale. Until then, the Danish findings offer a plausible, testable hypothesis rather than a reason to change prescribing on their own, but they add weight to the case for researching whether a drug already used by a huge share of people with diabetes could be doing more than protecting their hearts.
